611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Lovely But Dangerous, Wood Fires Bring Health Risks'Prehab' Before Surgery Helps Speed Seniors' RecoveryFlu Cases Are Spiking Early, Suggesting Tough Season AheadHealth Tip: Remedies for ConstipationAs Cases of Vaping-Linked Illness Rise, CDC Points to Certain Brands as CulpritsAHA News: Could Fish Oil Fight Inflammation?One Boy's Battle Back From Mysterious Polio-Like IllnessHealth Tip: Advice on Home Wound CareOver 40% of Antibiotics Could Be 'Inappropriately' PrescribedRural Seniors Hurt by Lack of Medical SpecialistsHealth Tip: Understanding Muscle SpasmsBlack Patients May Not Gain Heart Benefit From Low-Dose AspirinIs Pot Use a Heart Risk After Surgery?E. Coli Outbreak Spurs Packaged Salad WarningHealth Tip: Should I Get a Cholesterol Test?Are Superbugs Making Themselves at Home in Your Makeup Bag?Sometimes, Aspirin May Be Enough to Ease MigrainesDangers of 'Superbug' Germs Greater Than BelievedAdditives to E-Cigarettes May Be Upping Health DangersMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesVirtual Doc Visits Suffice for Many With Neurological DisordersBPA Levels in Humans Are Underestimated: StudyCleaner Air Quickly Brings Big Health Benefits, Study FindsAll 50 States Now Reporting Cases of Severe Vaping-Linked Lung Injury3 Drugs for Severe Epileptic Seizures Are Equally Effective: StudyStudy Casts Doubt on Use of Common Heart Failure Drugs'Mobile Stroke Units' Help Rush Treatment to PatientsDistracted by Their Smartphones, Pedestrians Are Landing in the ERVaping May Have Triggered Lung Illness Typically Only Seen in MetalworkersMore Than 100 E. Coli Illnesses Now Linked to Romaine LettuceLow-Dose Aspirin Might Cut Cancer Risk, Especially for Overweight PeopleEspecially in the Young, Cholesterol Is No Friend to the HeartAre E-Scooters a Quick Ticket to the ER?Uncontrolled Asthma a Danger to Pregnant Women, BabiesHealth Tip: Common Causes of Knee PainSome Cities' Smog Can Ruin Your VacationParkinson's Treatment Has Unexpected Side EffectHeart Attack at 44 Helped Her Realize Diabetes' DangersCleaner Teeth, Healthier Heart?Obesity Might Weaken Some Drugs' Effectiveness Against AFibHow to Prevent Holiday HeadachesAir Pollution May Up Glaucoma RiskHealth Tip: Causes of Stomach UlcersHealth Tip: Treating ShinglesLeg Pain Could Spell Peripheral Artery Disease for SomeEven in Small Doses, Air Pollution Harms Older AmericansDon't Let Allergies Spoil Your HolidaysGot Chronic Heartburn? Easy Does It During the Thanksgiving FeastAHA News: Flu Prevention Strategies Beyond Getting a Shot and Washing Your HandsUltrasound Treatment Might Ease Parkinson's Tremors
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Obesity Might Weaken Some Drugs' Effectiveness Against AFib

HealthDay News
by -- Steven Reinberg
Updated: Dec 2nd 2019

new article illustration

WEDNESDAY, Nov. 27, 2019 (HealthDay News) -- Millions of Americans have the potentially dangerous irregular heartbeat known as atrial fibrillation.

Now, research suggests that being obese might undercut the effectiveness of certain drugs meant to treat AFib.

The new study followed more than 300 patients listed in the University of Illinois at Chicago's AFib Registry. Researchers found that a class of medicines called sodium channel blockers, which are often used to treat AFib, were less effective in obese patients.

In fact, the recurrence rate for the heart arrhythmia was 30% for obese patients taking sodium channel blockers, compared with 6% for non-obese patients.

That could be bad news for many patients, since obesity is a big risk factor for AFib, said a team led by Dr. Dawood Darbar, head of cardiology at the university's College of Medicine.

Still, obese patients may have a viable option: Darbar's team found that another class of drugs, called potassium channel blockers, worked better in obese patients.

"This is the first time anyone has shown that there is a differential response to anti-arrhythmic drugs for AFib," Darbar said in a university news release. "As 50% of the patients in our AFib Registry are obese, this provided us with a unique opportunity to determine whether obesity affected response to drug treatment."

Dr. Satjit Bhusri, a cardiologist at Lenox Hill Hospital in New York City, said the new findings make sense, given what's known about how sodium channel blockers work.

"Most antiarrhythmic drugs distribute throughout the body and are absorbed by many organs," explained Bhusri, who wasn't involved in the Chicago study. "Since these drugs require a large dose to reach a steady level in the blood, those patients that are obese may well be under-treated -- they may require increased dosing compared to thinner patients."

But upping the dose could lead to unwanted side effects, he added, so doctors may want to consider other treatment options in obese patients.

According to Bhusri, sodium channel blockers commonly prescribed for AFib include quinidine, procainamide, felcianide and propafenone.

Darbar agreed that the new study offers obese patients a route to better treatment.

The obesity epidemic is increasing, he said, so "having treatment options to better manage AFib would greatly improve quality of life and could prevent the risk of serious complications, like stroke, which can cause early death."

Dr. Laurence Epstein is system director of electrophysiology at Northwell Health in Manhasset, N.Y. Reading over the new findings, he agreed that "treating atrial fibrillation remains a challenge."

"What we are learning is that all AFib is not the same," he said. "If you asked an oncologist how do you treat cancer, they would ask you, what type of cancer? The same is true for AFib. The present study adds additional support to the notion that all AFib is not the same, and we need to be tailoring treatment to individual patients."

The study was published online Nov. 27 in the journal JAMA Cardiology.

More information

The U.S. National Heart, Lung, and Blood Institute has more on atrial fibrillation.